Oxford BioMedica
Discover Realise

Pipeline

Our novel gene-based medicines and other collaborative development products have the potential to transform treatment prospects, thus improving the quality and duration of life for patients with debilitating and life threatening diseases.

Product (partner/funding) Indication Stage of development

Priority programmes (to be spun out or out-licensed)

______

CNS (Parkinson’s disease)
Phase I/II trial preparation
Ocular (corneal graft rejection)
Phase I/IIa trial preparation
Oncology (cancer, multiple)
Research

Other candidates (to be spun out or out-licensed)

______

Ocular (Wet AMD)
Phase I trial completed
Oncology (cancer, multiple)
Phase II ongoing
 

Oxford BioMedica partnered products (development milestones and royalties)

______

Ocular (Stargardt disease)
Phase I/IIa trial ongoing
Ocular (Usher syndrome type 1B)
Phase I/IIa trial ongoing

IP enabled and royalty bearing products (process development and bioprocessing revenues, and royalties)

______

Oncology (cancer, multiple)
Phase II/III
Oncology (cancer, multiple)
Research
Oncology (cancer, multiple)
Phase II
Undisclosed
Phase I/II
Undisclosed
Phase I/II

Notes:

Click on a product/programme name to find out more